ProtoKinetix' AAGP(TM) More Than Doubles Stem Cell Recovery

VANCOUVER, British Columbia--(Business Wire)--Research in the field of stem cell therapy has exploded over the
last few years. Stem cells are immature, unprogrammed cells that have
the ability to grow into different kinds of tissue. Recent studies
have shown that stem cell therapies offer real hope for the treatment
of a wide range of diseases such as leukemia, diabetes, spinal cord
injury, heart damage, brain damage, blood cell formation and even hair
loss.

As a result of current findings, major initiatives are being
conducted by large pharmaceutical and biotechnology companies,
research establishments and universities around the world, to develop
stem cell therapies in regenerative medicine. Unfortunately the demand
for stem cells outstrips the supply. One of the bottlenecks in this
rapidly expanding industry and ultimate commercialization is the
ability to deliver sufficient supply of stem cells to advance these
programs. Currently there are a vast number of stem cells lost in the
process of cultivation, storage, transportation and recovery from
cryopreservation.

ProtoKinetix (OTCBB:PKTX) reports that repeated tests have
confirmed that the addition of AAGP(TM) to the cryopreservation
process more than doubles the useable inventory of these very delicate
and valuable cells.

About ProtoKinetix

ProtoKinetix Inc is a biotechnology company that has developed and
patented a family of synthetic anti-aging glycoproteins (AAGP(TM)) for
medicine and the biotechnology and cosmetic industries. PKTX is
currently in dialogue with major corporations and institutions who
have contacted the company about the broad range of applications for
AAGP(TM) products.

For more detailed information, please visit our new website at:
www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Some information
included in this press release contains statements that are
forward-looking. Such forward-looking information involves significant
risks and uncertainties that could affect anticipated results in the
future and, accordingly, these results may differ materially from
those expressed in any forward-looking statements made by or on behalf
of the Company. For a description of additional risks and
uncertainties, please refer to the Company's filings with the
Securities and Exchange Commission.

-0-
*T
Company Office
Ross L. Senior, LLB - President and CEO
Suite # 1500
885 West Georgia Street
Vancouver, BC V6C 3E8
*T

Investor Contact
ProtoKinetix Inc.
Blair Henderson, 604-687-9887

Copyright Business Wire 2008